Amixin IC film-coated tablets of 0.125 g, 3 pcs

Pharmacodynamics. amiksin ic (tiloron) is an immunomodulating and antiviral agent. stimulates the formation of α-, β-, γ-interferons in the body. the main producers of interferon in response to the administration of amixin ic are intestinal epithelial cells, hepatocytes, T-lymphocytes, neutrophils and granulocytes. after ingestion, the maximum production of interferon is determined in the sequence intestines – liver – blood after 4-24 hours. stimulates bone marrow stem cells, depending on the dose increases antibody formation, reduces the degree of immunodepression, restores the ratio of T-suppressors / T-helpers. effective against a wide range of viral infections, including against influenza viruses, other SARS, hepatitis a, b, c, herpes viruses. The mechanism of antiviral action is associated with inhibition of translation of virus-specific proteins in infected cells, as a result of which virus reproduction is inhibited.

When conducting research on animals (chicken and duck embryos), high antiviral activity of the drug against the causative agent of the highly pathogenic avian influenza (HPV) strain H5N1 was proven, as well as (when conducting experiments on chickens) significant immunostimulating and adjuvant activity against the antigens of the causative agent of HPV.

Pharmacokinetics. After oral administration, tyloron is rapidly absorbed in the gastrointestinal tract. Bioavailability is 60%. About 80% of the drug binds to blood plasma proteins. The drug does not undergo biotransformation and does not accumulate in the body. It is excreted practically unchanged with feces and urine in a ratio of 7: 1. T _½ is 48 hours.

Adults: treatment of viral hepatitis a, b, c, herpes infection, cytomegalovirus infection, as part of complex therapy of infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis and meningoencephalitis), urogenital and respiratory chlamydia; treatment and prevention of influenza and other SARS. to reduce the degree of immunodepression as part of the complex therapy of diseases accompanied by secondary induced immunodeficiency (caused by the influence of X-ray radiation, cytostatics, surgical interventions, etc.) and requiring immunocorrection.

Children older than 7 years: for the treatment of influenza and other SARS.

The drug is used internally after meals.

adults

Prevention of viral hepatitis A – 125 mg/week, for 6 weeks.

Treatment of viral hepatitis A – on the first day, 125 mg 2 times a day, after that – 125 mg with an interval of 48 hours. Course dose – 1.25 g.

Treatment of acute hepatitis B – 125 mg for the first 2 days, after that – 125 mg with an interval of 48 hours. Course dose – 2 g. In case of a long course of hepatitis B, the course dose can be increased to 2.5 g

With chronic hepatitis B – in the first 2 days, take 250 mg, after that – 125 mg with an interval of 48 hours. The course dose at the beginning of treatment is 2.5 mg. In the future, the drug is taken at a dose of 125 mg/week. The total course dose is from 3.75 to 5 m

With acute hepatitis C – in the first 2 days of treatment – 125 mg, after that – 125 mg with an interval of 48 hours. Course dose – 2.5 g.

With chronic hepatitis C – in the first 2 days of treatment – 250 mg, after that – 125 mg with an interval of 48 hours. Course dose at the beginning of treatment – 2.5 g. In the future, the drug is taken in a dose of 125 mg/week. The total course dose is 5 m

In the treatment of influenza and other acute respiratory viral infections – in the first 2 days of treatment, 125 mg, after that – 125 mg with an interval of 48 hours. The total course dose is 750 mg.

For the prevention of influenza and other SARS, take 125 mg once a week for 6 weeks.

For the treatment of herpetic, cytomegalovirus infection, take 125 mg for the first 2 days, then 125 mg with an interval of 48 hours. The total course dose is 2.5 g.

To reduce the degree of immunodepression as part of the complex therapy of diseases accompanied by secondary induced immunodeficiency and requiring immunocorrection – 125-250 mg/week, for 6 weeks. The maximum course dose is 1.5 g. Depending on immunological indicators and the course of the disease, the course of treatment can be repeated with an interval of 4 weeks between courses.

For urogenital and respiratory chlamydia, take 125 mg each in the first 2 days, after that – 125 mg each with an interval of 48 hours. Course dose – 1.25 g.

As part of the complex therapy of neuroviral infections – infectious-allergic and viral encephalomyelitis (multiple sclerosis, leukoencephalitis, uveoencephalitis and meningoencephalitis) – in the first 2 days, 125 mg, after that – 125 mg with an interval of 48 hours. Course dose – from 1.5 to 1.75 m

Children over the age of 7 years with uncomplicated forms of influenza or other acute respiratory viral infections take 60 mg once a day on the 1st, 2nd and 4th days from the start of treatment. Course dose – 180 mg. In the event of complications of influenza or other acute respiratory viral infections, the drug is taken at 60 mg/day on the 1st, 2nd, 4th, and 6th days from the start of treatment. Course dose – 240 mg.

Increased individual sensitivity to the components of the drug.

From the side of the skin and subcutaneous tissue: allergic reactions, including itching, rashes (in particular, urticaria).

Gastrointestinal tract: dyspeptic phenomena (in particular, nausea, heartburn).

Others: short-term fever.

The period of pregnancy and breastfeeding. there is no experience of using the drug during pregnancy and breastfeeding, so the drug should not be prescribed during this period.

Children. Do not use in children under 7 years of age.

Influence on the ability to drive vehicles and work with other mechanisms. Does not affect.

Compatible with antibiotics and means of traditional treatment of bacterial and viral diseases.

Cases of overdose of the drug amiksin ic are unknown.

In the original packaging at a temperature not higher than 25 °C.